Stem Point Capital LP has filed its 13F form on February 14, 2025 for Q4 2024 where it was disclosed a total value porftolio of $401 Billion distributed in 58 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Syndax Pharmaceuticals Inc with a value of $38B, Roivant Sciences Ltd. with a value of $32.1B, Immunovant, Inc. with a value of $27.7B, Merus N.V. with a value of $25.9B, and Crinetics Pharmaceuticals, Inc. with a value of $16.2B.

Examining the 13F form we can see an increase of $66.6B in the current position value, from $334B to 401B.

Stem Point Capital LP is based out at New York, NY

Below you can find more details about Stem Point Capital LP portfolio as well as his latest detailed transactions.

Portfolio value $401 Billion
Healthcare: $340 Billion
ETFs: $928 Million
Consumer Defensive: $75 Million

Stock Holdings Table Market Cap. of $10 Billions to $200 Billions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 58
  • Current Value $401 Billion
  • Prior Value $334 Billion
  • Filing
  • Period Q4 2024
  • Filing Date February 14, 2025
  • Form Type 13F-HR
  • Activity in Q4 2024
  • New Purchases 22 stocks
  • Additional Purchases 19 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 6 stocks
Track This Portfolio

Track Stem Point Capital LP Portfolio

Follow Stem Point Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stem Point Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Stem Point Capital LP with notifications on news.